Pharmacokinetics of the cytostatic drugs used in the CMF-regimen.
Forty-one clinical patients were studied on the first day of the first course of the CMF-regimen; administered by a fixed dosage scheme depending solely on body surface area of the patient in question. Parmacokinetic parameters were calculated for each drug: the data were analysed in conformity with the usual pharmacokinetic models. The results indicate a large pharmacokinetic variability, especially for cyclophosphamide (C). The large variability in plasma concentrations of C is presumed to be substantially attributable to the drug formula used.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000378:metabolism*; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008727:Methotrexate / Q000008:administration & dosage / Q000378:metabolism*; D008875:Middle Aged
D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate